The DNA damage response (DDR) encompasses the intricate network of cellular responses to DNA damage (Figure 2). Different exogenous and endogenous factors continuously generate an enormous ...

Big players have been carving out a niche in the small but thriving field of poly(ADP-ribose) polymerase (PARP) inhibitors, as long-awaited data roll out that validate the experimental approach.

One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

Credit: Dr Rebecca Marlow, The Institute of Cancer Research, London. Researchers at The Institute of Cancer Research, London, have increased our understanding of how a cancer drug called a PARP ...

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer.

Alison Halliday spoke to several of our researchers here at The Institute of Cancer Research, London, who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been ...

The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and ...

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, ...

The groundbreaking results of the OVATION 2 Study demonstrated a substantial 35% improvement in overall survival, equating to ...